Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?

Schizophrenia continues to be an illness with poor outcome. Most mechanistic changes occur many years before the first episode of schizophrenia; these are not reversible after the illness onset. A developmental mechanism that is still modifiable in adult life may center on intracortical glutathione...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lena Palaniyappan, Min Tae M. Park, Peter Jeon, Roberto Limongi, Kun Yang, Akira Sawa, Jean Théberge
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	glutathione glutamate psychosis schizophrenia redox antioxidant Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/863ee549baf34924a5417441eed46585
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:863ee549baf34924a5417441eed46585
record_format	dspace
spelling	oai:doaj.org-article:863ee549baf34924a5417441eed465852021-11-25T16:26:39ZIs There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?10.3390/antiox101117032076-3921https://doaj.org/article/863ee549baf34924a5417441eed465852021-10-01T00:00:00Zhttps://www.mdpi.com/2076-3921/10/11/1703https://doaj.org/toc/2076-3921Schizophrenia continues to be an illness with poor outcome. Most mechanistic changes occur many years before the first episode of schizophrenia; these are not reversible after the illness onset. A developmental mechanism that is still modifiable in adult life may center on intracortical glutathione (GSH). A large body of pre-clinical data has suggested the possibility of notable GSH-deficit in a subgroup of patients with schizophrenia. Nevertheless, studies of intracortical GSH are not conclusive in this regard. In this review, we highlight the recent ultra-high field magnetic resonance spectroscopic studies linking GSH to critical outcome measures across various stages of schizophrenia. We discuss the methodological steps required to conclusively establish or refute the persistence of <i>GSH-deficit</i> subtype and clarify the role of the central antioxidant system in disrupting the brain structure and connectivity in the early stages of schizophrenia. We propose in-vivo GSH quantification for patient selection in forthcoming antioxidant trials in psychosis. This review offers directions for a promising non-dopaminergic early intervention approach in schizophrenia.Lena PalaniyappanMin Tae M. ParkPeter JeonRoberto LimongiKun YangAkira SawaJean ThébergeMDPI AGarticleglutathioneglutamatepsychosisschizophreniaredoxantioxidantTherapeutics. PharmacologyRM1-950ENAntioxidants, Vol 10, Iss 1703, p 1703 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glutathione glutamate psychosis schizophrenia redox antioxidant Therapeutics. Pharmacology RM1-950
spellingShingle	glutathione glutamate psychosis schizophrenia redox antioxidant Therapeutics. Pharmacology RM1-950 Lena Palaniyappan Min Tae M. Park Peter Jeon Roberto Limongi Kun Yang Akira Sawa Jean Théberge Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
description	Schizophrenia continues to be an illness with poor outcome. Most mechanistic changes occur many years before the first episode of schizophrenia; these are not reversible after the illness onset. A developmental mechanism that is still modifiable in adult life may center on intracortical glutathione (GSH). A large body of pre-clinical data has suggested the possibility of notable GSH-deficit in a subgroup of patients with schizophrenia. Nevertheless, studies of intracortical GSH are not conclusive in this regard. In this review, we highlight the recent ultra-high field magnetic resonance spectroscopic studies linking GSH to critical outcome measures across various stages of schizophrenia. We discuss the methodological steps required to conclusively establish or refute the persistence of <i>GSH-deficit</i> subtype and clarify the role of the central antioxidant system in disrupting the brain structure and connectivity in the early stages of schizophrenia. We propose in-vivo GSH quantification for patient selection in forthcoming antioxidant trials in psychosis. This review offers directions for a promising non-dopaminergic early intervention approach in schizophrenia.
format	article
author	Lena Palaniyappan Min Tae M. Park Peter Jeon Roberto Limongi Kun Yang Akira Sawa Jean Théberge
author_facet	Lena Palaniyappan Min Tae M. Park Peter Jeon Roberto Limongi Kun Yang Akira Sawa Jean Théberge
author_sort	Lena Palaniyappan
title	Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
title_short	Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
title_full	Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
title_fullStr	Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
title_full_unstemmed	Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
title_sort	is there a glutathione centered redox dysregulation subtype of schizophrenia?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/863ee549baf34924a5417441eed46585
work_keys_str_mv	AT lenapalaniyappan isthereaglutathionecenteredredoxdysregulationsubtypeofschizophrenia AT mintaempark isthereaglutathionecenteredredoxdysregulationsubtypeofschizophrenia AT peterjeon isthereaglutathionecenteredredoxdysregulationsubtypeofschizophrenia AT robertolimongi isthereaglutathionecenteredredoxdysregulationsubtypeofschizophrenia AT kunyang isthereaglutathionecenteredredoxdysregulationsubtypeofschizophrenia AT akirasawa isthereaglutathionecenteredredoxdysregulationsubtypeofschizophrenia AT jeantheberge isthereaglutathionecenteredredoxdysregulationsubtypeofschizophrenia
_version_	1718413148707356672

Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?

Ejemplares similares